Novo returned to reinvest in the neuromuscular disorder therapy developer in a round that will fund the progress of its lead candidate through a phase 1 clinical trial.
US-based musculoskeletal disease drug developer Edgewise Therapeutics completed a $95m series C round on Tuesday that included pharmaceutical firm Novo.
Hedge fund manager Viking Global Investors led the round, which also featured new investors Janus Henderson Investors, Surveyor Capital, RA Capital Management, Cormorant Asset Management, Logos Capital and Wellington Management.
The participants were filled out by existing backers OrbiMed, US Venture Partners (USVP), Deerfield Management, New Leaf Ventures and CureDuchenne Ventures, the investment arm of non-profit research organisation CureDuchenne.
Edgewise…
